Thu, May 22, 7:07 PM (31 days ago)
**Nu-Med Plus, Inc. (NUMP) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated in Q1 2025. - **Profit Margins:** Operating loss of $18,700,000, slightly improved from $20,579,000 in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $0 in Q1 2025, compared to an outflow of $450,000 in Q1 2024. - **Earnings Changes:** Net loss reduced to $19,933,000 in Q1 2025 from $21,826,000 in Q1 2024. - **Cash Position:** Cash on hand was $2,373,000 as of March 31, 2025. **Quarterly Performance Discussion:** - **Operating Expenses:** Decreased by $1,879,000, primarily due to a reduction in professional and consulting fees. - **Interest Expense:** Slightly decreased to $1,233,000. - **Liabilities:** Increased to $240,202,000, mainly due to accounts payable and related party payables. **Trends and Uncertainties:** - **Funding:** The company is reliant on equity sales and shareholder loans to fund operations. - **Going Concern:** Substantial doubt about the ability to continue as a going concern due to insufficient funds to execute the business plan. - **Future Operations:** Plans to seek additional financing to cover $1,200,000 in planned expenditures for the next 12 months. **Future Impact:** - **Development:** Product development is suspended until further capital infusion. - **Market Entry:** Aims to penetrate the nitric oxide delivery market with cost-effective solutions. - **Regulatory:** FDA approval is required for medical uses, which is a lengthy and expensive process. **Ticker:** NUMP **Conclusion:** Nu-Med Plus, Inc. faces significant financial challenges, with no revenue and substantial operating losses. The company's ability to continue operations is dependent on securing additional funding. The focus remains on developing nitric oxide delivery technologies, but regulatory hurdles and financial constraints pose substantial risks.